J&J And India’s J.B. Chemicals On Collision Course As Sale Of Russian OTC Business Hits Snag
This article was originally published in PharmAsia News
J&J’s sudden claim for funds from an escrow account has sparked speculation on the future of the deal with J.B. Chemicals.
You may also be interested in...
MUMBAI - Less than three months after agreeing to sell its Russia-CIS prescriptions business, Indian drug maker J.B. Chemicals & Pharmaceuticals Ltd. has called-off its deal with fellow Indian drug maker Dr. Reddy's Laboratories Ltd.
Johnson & Johnson expands its consumer health presence in Russia and other Eastern European markets with the acquisition of several OTC brands from J.B. Chemicals & Pharmaceuticals
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.